Evidence map›Paper›PMID 30902103›Full record

ArticleJournal of translational medicine2019

Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy.

Kurt D Ristroph, Jie Feng, Simon A McManus, Yingyue Zhang, Kai Gong, Hanu Ramachandruni, Claire E White, Robert K Prud'homme

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. ACS infectious diseases · 2020
    Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Kurt D RistrophDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA.
Jie FengDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA.
Simon A McManusDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA.
Yingyue ZhangDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA.
Kai GongDepartment of Civil and Environmental Engineering, Princeton University, Princeton, NJ, 08854, USA.
Hanu RamachandruniMedicines for Malaria Venture, Route de Pré-Bois 20, 1215, Meyrin, Switzerland.
Claire E WhiteDepartment of Civil and Environmental Engineering, Princeton University, Princeton, NJ, 08854, USA.
Robert K Prud'hommeDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, 08854, USA. prudhomm@princeton.edu.ORCID 0000-0003-2858-0097
Princeton University · USMedicines for Malaria Venture · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOZ439 is a new chemical entity which is active against drug-resistant malaria and shows potential as a single-dose cure. However, development of an oral formulation with desired exposure has proved problematic, as OZ439 is poorly soluble (BCS Class II drug). In order to be feasible for low and middle income countries (LMICs), any process to create or formulate such a therapeutic must be inexpensive at scale, and the resulting formulation must survive without refrigeration even in hot, humid climates. We here demonstrate the scalability and stability of a nanoparticle (NP) formulation of OZ439. Previously, we applied a combination of hydrophobic ion pairing and Flash NanoPrecipitation (FNP) to formulate OZ439 NPs 150 nm in diameter using the inexpensive stabilizer hydroxypropyl methylcellulose acetate succinate (HPMCAS). Lyophilization was used to process the NPs into a dry form, and the powder's in vitro solubilization was over tenfold higher than unprocessed OZ439.

methodsIn this study, we optimize our previous formulation using a large-scale multi-inlet vortex mixer (MIVM). Spray drying is a more scalable and less expensive operation than lyophilization and is, therefore, optimized to produce dry powders. The spray dried powders are then subjected to a series of accelerated aging stability trials at high temperature and humidity conditions.

resultsThe spray dried OZ439 powder's dissolution kinetics are superior to those of lyophilized NPs. The powder's OZ439 solubilization profile remains constant after 1 month in uncapped vials in an oven at 50 °C and 75% RH, and for 6 months in capped vials at 40 °C and 75% RH. In fasted-state intestinal fluid, spray dried NPs achieved 80-85% OZ439 dissolution, to a concentration of 430 µg/mL, within 3 h. In fed-state intestinal fluid, 95-100% OZ439 dissolution is achieved within 1 h, to a concentration of 535 µg/mL. X-ray powder diffraction and differential scanning calorimetry profiles similarly remain constant over these periods.

conclusionsThe combined nanofabrication and drying process described herein, which utilizes two continuous unit operations that can be operated at scale, is an important step toward an industrially-relevant method of formulating the antimalarial OZ439 into a single-dose oral form with good stability against humidity and temperature.

Indexed as

Oral SpraysPowdersAdamantaneAdministration, OralChemistry, PharmaceuticalDesiccationDrug StabilityFreeze DryingHumansMalariaNanoparticlesNebulizers and VaporizersPeroxidesSolubilityWaterAdamantaneartefenomelOral SpraysPeroxidesPowdersWaterArtefenomelDrug deliveryDrug solubilizationFlash NanoPrecipitationHydrophobic ion pairingMalariaNanocarrierOral therapeuticOZ439Spray drying

Identifiers

PMID30902103
PMCPMC6431012
OpenAlexW2940694051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.